Quantcast

Latest Lactams Stories

2014-07-30 08:33:01

Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo...

2014-07-28 23:07:00

LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Tadalafil Industry, 2009-2019” to its store. Complete report is available at http://www.lifescienceindustryresearch.com/market-research-report-on-global-and-chinese-tadalafil-industry-2009-2019.html. Dallas,TX (PRWEB) July 28, 2014 This is a professional and in-depth market survey on Global and Chinese Tadalafil industry. The report firstly reviews the basic information of Tadalafil...

2014-07-27 23:01:51

The Firm is currently representing clients in Risperdal lawsuits that similarly allege the atypical antipsychotic medication caused gynecomastia, a condition categorized by male breast development. New York, NY (PRWEB) July 27, 2014 A consolidated litigation that now includes more than 600 Risperdal lawsuit (http://www.lawreward.com/risperdal/) filings is proceeding in the Philadelphia Court of Common Pleas, where a meeting has been scheduled in August to discuss claims involving the...

2014-07-27 12:20:59

LifeScienceIndustryResearch.com adds Latest Report on "Global and Chinese Vardenafil (CAS 224785-90-4) Industry, 2009-2019 Market Research Report" to its store. DALLAS, July 27, 2014 /PRNewswire-iReach/ -- This is a professional and in-depth market survey on Global and Chinese Vardenafil (CAS 224785-90-4) industry. The report firstly reviews the basic information of Vardenafil (CAS 224785-90-4) including its classification, application and manufacturing technology. The report then...

2014-07-24 23:10:39

The DrugNews Center is the largest source for prescription drug and medical device warnings, research and legal news. Visit http://www.DrugNews.net today. Chicago, IL (PRWEB) July 24, 2014 The prescription drug safety center DrugNews.net has added new research information to the site for patients who have taken popular erectile dysfunction drugs like Viagra. Following a recent study that found men who’d taken the drugs had a higher rate of skin cancer*, a new report offers an...

2014-07-23 23:16:39

The Firm is representing numerous clients in Risperdal lawsuits who allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic medication. New York, NY (PRWEB) July 22, 2014 The Pennsylvania judge overseeing hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) in the Philadelphia Court of Common Pleas won’t reconsider his decision to deny punitive damages in cases alleging the medication caused plaintiffs to develop...

2014-07-17 23:04:12

LifeScienceIndustryResearch.com adds latest report on “Global and Chinese Sildenafil Citrate (CAS 171599-83-0) Industry, 2009-2019 Market Research Report” to its store. Inquire before buying this report at http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=15625. Dallas, TX (PRWEB) July 17, 2014 This is a professional and in-depth market survey on Global and Chinese Sildenafil Citrate (CAS 171599-83-0) industry. The report firstly reviews the basic information of...

2014-07-17 04:20:49

LUGANO, Switzerland and TOKYO, July 17, 2014 /PRNewswire/ -- Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care. Helsinn, the Swiss Group focused on building quality cancer care, and Chugai Pharmaceutical Co., Ltd. today announced that exclusive rights to...

2014-07-14 08:26:29

Submission based on first head-to-head study vs. oral treatments in real world context TITUSVILLE, N.J., July 14, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic INVEGA(®)...

2014-07-11 08:24:35

Agreement with Biotie ends option for purchase and allows Neurelis to advance development of NRL-1 in preparation for NDA filing SAN DIEGO, July 11, 2014 /PRNewswire/ -- Neurelis, Inc. ("Neurelis") today announced an agreement with Biotie Therapies Corp. ("Biotie") to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients who experience acute repetitive...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related